Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 10/20 | 0.49 |
| ▸ | VDR | P11473 | 5/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | BCAT2 | O15382 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5516294 | 0.99 | NR1H4 (0.48) | NR1H4VDRL3MBTL1BCAT2MAPT | |
| SCHEMBL5508885 | 0.94 | NR1H4 (0.52) | NR1H4VDRL3MBTL1IDH1CYP2C9 | |
| SCHEMBL14383716 | 0.93 | NR1H4 (0.52) | NR1H4VDRL3MBTL1MAPTIDH1 | |
| SCHEMBL5509930 | 0.93 | RPS6KB1 (0.45) | NR1H4VDRL3MBTL1BCAT2MAPT | |
| SCHEMBL14383505 | 0.93 | MAPT (0.49) | NR1H4VDRL3MBTL1MAPTTHRB | |
| SCHEMBL14383439 | 0.93 | L3MBTL1 (0.45) | NR1H4VDRL3MBTL1BCAT2MAPT | |
| Hydrochloric Acid SCHEMBL5514901 | 0.93 | NR1H4 (0.51) | NR1H4VDRL3MBTL1MAPTIDH1 | |
| Hydrochloric Acid SCHEMBL5512834 | 0.93 | MAPT (0.48) | NR1H4VDRL3MBTL1MAPTTHRB | |
| Hydrochloric Acid SCHEMBL5513942 | 0.92 | L3MBTL1 (0.44) | NR1H4VDRL3MBTL1BCAT2MAPT | |
| Hydrochloric Acid SCHEMBL5527007 | 0.92 | NR1H4 (0.51) | NR1H4VDRL3MBTL1BCAT2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082635-A1 | Viricide against hepatitis virus; polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2004-04-29 | — | — | US | claimed |
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2015-01-22 | — | — | US | disclosed |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2015-01-22 | — | — | US | disclosed |
| US-8871785-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-8022083-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022083-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-7645747-B2 | Improved pharmacokinetic properties, oral bioavailability; side effect reduction | GILEAD SCIENCES, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7429565-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | NR1H4 3359/4885VDR 2212/4885L3MBTL1 2434/4885 |
| US-20040082635-A1 | Viricide against hepatitis virus; polymerase inhibitor | HAVCR2, ZC3HAV1, POLR1C | NR1H4 484/4885VDR 3852/4885L3MBTL1 3799/4885 |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | NR1H4 3359/4885VDR 2212/4885L3MBTL1 2434/4885 |
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | NR1H4 3359/4885VDR 2212/4885L3MBTL1 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.